Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Phase II study of glofitamab in patients with R/R LBCL

Michael Dickinson • 11 Jun 2022
EHA 2022
Aggressive & Diffuse Large B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Glofitamab

Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the design and results of the pivotal Phase II trial evaluating glofitamab in patients with relapsed/refractory (R/R) aggressive large B-cell lymphoma (LBCL) who have been treated with CAR-T therapy (NCT03075696). The trial reported high and durable complete remission rates. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Funding, research & consulting: Novartis, Roche, Kite/Gilead, BMS, Takeda

More from Michael Dickinson

4:18
Pembrolizumab monotherapy for older/ABVD-ineligible patients with Hodgkin lymphoma
Michael Dickinson • 16 Jun 2023
3:48
COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCL
Michael Dickinson • 16 Jun 2023
10:25
Key highlights in NHL: updates in MCL, the role of transplantation, and novel bispecific antibodies
Michael Dickinson et al. • 12 Dec 2022
3:49
The challenges in developing bispecific antibodies for non-Hodgkin lymphoma
Michael Dickinson • 30 Sep 2022

Related Videos

1:15
Tackling PD1i resistance in Hodgkin lymphoma
Graham Collins • 29 Apr 2024
3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
2:00
BTK degraders in CLL and lymphoma: a Phase I trial of NX-5948
Dima El-Sharkawi • 28 Apr 2024
2:39
The role of bispecific antibodies in the treatment landscape for R/R DLBCL
Wendy Osborne • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals